Exelixis Inc (EXEL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jul 03 2026 to Jul 04 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Exelixis Inc   (NASDAQ: EXEL)


Exelixis Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Exelixis Inc's ROI in the second quarter of 2026?
Exelixis Inc achieved a return on average invested assets (ROI) of 82.05 % in its second quarter of 2026 a new company high.

Despite the deterioration in its net income, company has improved ROI compared to the first quarter of 2026.

Within the Healthcare sector 16 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 15 to 56.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jul 03 2026)
II. Quarter		 (Apr 03 2026)
I. Quarter		 (Jan 02 2026)
IV. Quarter		 (Oct 03 2025)
III. Quarter		 (Jul 04 2025)
II. Quarter
Y / Y Investment Change TTM -6.54 % -5.24 % -3 % -1.99 % -1.16 %
Y / Y Net Income Change TTM 37.6 % 23.96 % 54.42 % 95.93 % 165.52 %
Investment (TTM) in Millions 2,132 2,223 2,439 2,450 2,342
Return On Investment (TTM) 82.05 % 77.71 % 71.31 % 63.48 % 55.73 %
EXEL's Overall Ranking # 56 # 15 # 10 # 6 # 69
Seq. Investment Change TTM -2.22 % -2.23 % -1.08 % -1.17 % -0.86 %
Seq. Net Income Change TTM 3.24 % 6.55 % 11.13 % 12.57 % -7 %
Net Income (TTM) in Millions 1,896 1,837 1,724 1,551 1,378

EXEL Company Profile >> Back to EXEL Roi Comparisons >> See Annual EXEL Return On Investment



Return On Investment EXEL's Ranking
Within: No.
Industry # 4
Sector # 17
Overall # 56

Return On Investment Statistics
High Average Low
82.05 %
5.27 %
-105.94 %
(Jul 03 2026)   (Apr 03 2015)







Financial Statements
Exelixis Inc's II. Quarter Investments $ 2,132 Millions EXEL's Balance sheet
Exelixis Inc's II. Quarter Income $ 475 Millions Quarterly EXEL's Income Statement
EXEL's Income by Division See EXEL's Income by Division


EXEL Annual Return On Investment (Jan 02 2026)
2025		 (Jan 03 2025)
2024		 (Dec 29 2023)
2023		 (Dec 30 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 2,439 2,544 2,548 2,747 2,279
Y / Y Investment Growth -4.13 % -0.16 % -7.25 % 20.56 % 17.9 %
Net Income in Millions 1,724 1,203 465 417 525
Y / Y Net Income Growth 43.3 % 158.53 % 11.68 % -20.67 % 369.86 %
Annual Return On Investment 70.68 % 47.29 % 18.26 % 15.17 % 23.05 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 70.68 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
EXEL's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for EXEL's Competitors
Subscribers only: Roi for Exelixis Inc's Suppliers
Subscribers only: Return On Investment for EXEL's Customers

Other Ratios
EXEL's Roa EXEL's Inventory Turnover Ratio EXEL's Growth Rates EXEL's Dividend Statistics
EXEL's Profitability Ratios EXEL's Asset Turnover Ratio EXEL's Dividend Growth
EXEL's Roe EXEL's Valuation Ratios EXEL's Financial Strength Ratios EXEL's Dividend Payout Ratio



Companies with similar Return On Investment at Jul 03 2026, within Healthcare Sector ROI
Omeros Corporation  198.34 %
Elutia Inc   191.75 %
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %

Date modified: 2026-09-13T23:29:29+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.